Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Obiltoxaximab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Elusys Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Heat Biologics (NightHawk Biosciences) Completes Acquisition of Elusys Therapeutics
Details : Pursuant to this acquisition, NightHawk announced it plans to migrate manufacturing of ANTHIM® to its planned Scorpion biomanufacturing facility in Manhattan, Kansas, which is being constructed to support development of commercial-scale biologics and la...
Product Name : Anthim
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
April 20, 2022
Lead Product(s) : Obiltoxaximab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Elusys Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
Details : New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and other cellular products.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 25, 2022
Lead Product(s) : Obiltoxaximab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Elusys Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Heat Biologics Announces Planned Acquisition of Elusys Therapeutics
Details : The strategic acquisition of Elusys is intended to enhance Heat’s immunotherapy portfolio and further position Heat to take a lead role in the biodefense space. The addition of ANTHIM (obiltoxaximab) Injection, together with Heat’s previously announc...
Product Name : Anthim
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 21, 2021
Lead Product(s) : Obiltoxaximab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Elusys Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : PTX-35
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study of PTX-35 in Healthy Volunteers
Details : PTX-35 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 11, 2021
Lead Product(s) : PTX-35
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The patent covers compositions of matter that are part of Heat's gp96 platform (antigen presentation, T cell activation, TLR activation) in combination with Inducible T cell Co-stimulator (ICOS) ligand or ICOSL, a T cell immune booster, in a single thera...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 07, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Heat Biologics Issued Key Patent on Combination Platform Therapy
Details : Heat Biologics been issued a patent (US Patent No. 10,758,611) by the U.S. Patent and Trademark Office (USPTO) covering compositions of matter that are part of Heat's gp96 platform in combination with a T cell costimulatory agonist in a single therapy.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 02, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Heat Biologics Highlights Importance of T cell Immunity to Prevent COVID-19
Details : Heat's COVID-19 vaccine is designed to drive T cell immunity, while also activating antibody responses and innate immunity, which may complement conventional COVID-19 vaccines in combination approaches by enhancing T cell immunity.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 05, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35
Details : First patient has been treated in the Company's first-in-human Phase 1 clinical trial evaluating PTX-35, the first antibody product candidate developed by Heat Biologics' Pelican Therapeutics subsidiary.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 22, 2020
Heat Biologics Announces FDA Clearance of Investigational New Drug (IND) Application for PTX-35
Details : Preclinical studies have demonstrated PTX-35, in combination with antigen-driven immunotherapies, resulted in enhanced anti-tumor properties, including potent proliferation of antigen-specific T cells, production of effector cytokines and augmented effec...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 08, 2020
Details : Median overall survival (OS) of 28.7 months for HS-110 in combination with nivolumab in previously treated checkpoint inhibitor naïve non-small cell lung cancer (NSCLC) patients.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 14, 2020